Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients
about
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursDiagnosis and treatment of carcinoid tumors.The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Systemic chemotherapy of liver tumors.Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.Update on the treatment of neuroendocrine tumors.Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and ImmunohistochemistryA review of the use of somatostatin analogs in oncologyFrom somatostatin to octreotide LAR: evolution of a somatostatin analogueUpdate on management of midgut neuroendocrine tumors.Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.Evolving treatment strategies for management of carcinoid tumors.Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.Telotristat ethyl: a new option for the management of carcinoid syndrome.Low Grade Neuroendocrine Tumors of the Lung.Management of the hormonal syndrome of neuroendocrine tumors.Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.Tumors of the Pancreatic Body and Tail.Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.Advanced typical and atypical carcinoid tumours of the lung: management recommendations.Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.
P2860
Q24685837-18AEF1A0-456D-4230-B5DA-9AC2FD35BF75Q33196127-2F964A72-EFC0-4C8B-9F8B-70A37776C4B1Q34031906-E2E7238F-43A4-43A3-8B09-0A00FA999FE0Q34110952-0113B070-81CB-4AC9-9947-11A362E2EB74Q34992833-D429D3C5-696F-4E8C-807A-1289DEB0DF3EQ35020349-EAFCE853-AC74-45F5-B7B1-236EB521BCE1Q35576166-C70203AD-AED2-4FC5-A8C9-1BF822AB3DDEQ35755390-4CCEFD04-FBAD-467D-8C5C-D143D8BEEB9CQ35760798-4CDBD7AE-0545-4956-8F09-C3F69F236F1BQ36090916-3580CE7D-4F48-4DC4-8585-52C754E28ED6Q36833161-9195BC57-9BC6-4F01-80F7-78186CDDAF39Q36919554-3E40E4B3-AB44-4B01-A9C1-0C92E34C6711Q37025143-4268EAC3-4121-4FE7-B76E-216BF066A86DQ37077832-0E98601C-CC54-4D1E-A3A4-35A5DD8F8C9AQ37314269-44982AFC-CAA0-4065-B3E2-37CE41FB3009Q37859615-65EE2898-09E7-43C0-B328-AB92E247FB57Q38124702-C45A5E47-8B95-47B2-9F6A-BE8A64D8117DQ38647297-05EE0D36-0715-446C-A925-D8AECB32760DQ38755167-3A4EC3FF-9A30-404B-9E5F-BA363F21EEDAQ39000212-A79DF1AE-B4B7-4CF5-89A8-0C89756D6798Q39403750-9363D32B-874A-4D2C-9C41-F7DF78FF3C03Q41832570-6D328CEB-83CA-491B-BD5F-A813F16A9F22Q43606558-F61A01A6-D694-4CAD-970B-32C94E9EB5DCQ43921041-D9A8EFA7-53B2-4288-8C8E-DACE62BF4E25Q44148184-285EFA80-FB8F-4DFC-A024-F043A99F011DQ46141893-283CDDEB-6442-437C-BEC4-EE0E783F8195Q46946845-5D3248DF-C303-406F-99DD-701911A87EF7Q46950109-CA243D2E-6D27-437C-986B-5DB559E9CD35Q47944297-68FC7110-3387-4B77-94BC-757ED5EED3C8Q53530061-FC6FFB75-56E8-4467-B445-D474B7E01975Q55332915-5FA2215D-6CD3-4EA4-A8DC-3B4FE7A24D7FQ55502689-A0F9A9F7-323D-4B7D-A189-25C0446CE26A
P2860
Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Treatment of the carcinoid syn ...... ospective study in 39 patients
@ast
Treatment of the carcinoid syn ...... ospective study in 39 patients
@en
Treatment of the carcinoid syn ...... ospective study in 39 patients
@nl
type
label
Treatment of the carcinoid syn ...... ospective study in 39 patients
@ast
Treatment of the carcinoid syn ...... ospective study in 39 patients
@en
Treatment of the carcinoid syn ...... ospective study in 39 patients
@nl
prefLabel
Treatment of the carcinoid syn ...... ospective study in 39 patients
@ast
Treatment of the carcinoid syn ...... ospective study in 39 patients
@en
Treatment of the carcinoid syn ...... ospective study in 39 patients
@nl
P2093
P2860
P356
P1433
P1476
Treatment of the carcinoid syn ...... ospective study in 39 patients
@en
P2093
E Genestin
J A Chayvialle
J Blumberg
J M Raymond
P Bernades
P2860
P304
P356
10.1136/GUT.39.2.279
P407
P577
1996-08-01T00:00:00Z